Recombinant mouse PD-L1 protein (Fc Chimera Active) is a Mouse Fragment protein, in the 19 to 238 aa range, expressed in HEK 293, with >95% purity, < 1 EU/µg endotoxin level and suitable for SDS-PAGE, ELISA.
Images
Key facts
- Purity
>95% SDS-PAGE
- Endotoxin level
< 1 EU/µg
- Expression system
HEK 293 cells
- Tags
Fc tag C-Terminus
- Applications
SDS-PAGE, ELISA
- Biologically active
Yes
Amino acid sequence
F T I T A P K D L Y V V E Y G S N V T M E C R F P V E R E L D L L A L V V Y W E K E D E Q V I Q F V A G E E D L K P Q H S N F R G R A S L P K D Q L L K G N A A L Q I T D V K L Q D A G V Y C C I I S Y G G A D Y K R I T L K V N A P Y R K I N Q R I S V D P A T S E H E L I C Q A E G Y P E A E V I W T N S D H Q P V S G K R S V T T S R T E G M L L N V T S S L R V N A T A N D V F Y C T F W R S Q P G Q N H T A E L I I P E L P A T H P P Q N R T
Reactivity data
| Application | Reactivity | Dilution info | Notes |
|---|---|---|---|
Application SDS-PAGE | Reactivity Reacts | Dilution info - | Notes - |
Application ELISA | Reactivity Reacts | Dilution info - | Notes - |
Associated Products
Select an associated product type
7 products for Alternative Product
Target data
Function
Plays a critical role in induction and maintenance of immune tolerance to self (PubMed:11238124). As a ligand for the inhibitory receptor PDCD1/PD-1, modulates the activation threshold of T-cells and limits T-cell effector response (PubMed:11238124). Through a yet unknown activating receptor, may costimulate T-cell subsets that predominantly produce interleukin-10 (IL10) (PubMed:11015443, PubMed:12719480).The PDCD1-mediated inhibitory pathway is exploited by tumors to attenuate anti-tumor immunity and escape destruction by the immune system, thereby facilitating tumor survival (PubMed:12218188, PubMed:27281199). The interaction with PDCD1/PD-1 inhibits cytotoxic T lymphocytes (CTLs) effector function (PubMed:12218188). The blockage of the PDCD1-mediated pathway results in the reversal of the exhausted T-cell phenotype and the normalization of the anti-tumor response, providing a rationale for cancer immunotherapy (PubMed:12218188).
Alternative names
Programmed cell death 1 ligand 1, PD-L1, PDCD1 ligand 1, Programmed death ligand 1, B7 homolog 1, B7-H1, Pdcd1l1, Pdcd1lg1, Pdl1, B7h1, Cd274
Recommended products
Recombinant mouse PD-L1 protein (Fc Chimera Active) is a Mouse Fragment protein, in the 19 to 238 aa range, expressed in HEK 293, with >95% purity, < 1 EU/µg endotoxin level and suitable for SDS-PAGE, ELISA.
Key facts
- Purity
>95% SDS-PAGE
- Endotoxin level
< 1 EU/µg
- Expression system
HEK 293 cells
- Tags
Fc tag C-Terminus
- Applications
SDS-PAGE, ELISA
- Biologically active
Yes
- Biological activity
Measured by its binding ability in a functional ELISA. Immobilized ab221310 at 5 μg/mL (100 μL/well) can bind Recombinant mouse PD1 protein (Active) (Biotin) (ab246151) with a linear range of 0.313-5 μg/mL.
Measured by its binding ability in a functional ELISA. Immobilized Recombinant Mouse CD80 protein (Fc Chimera) (ab207101) at 5 μg/mL (100 μL/well) can bind ab221310 with a linear range of 0.16-2.5 μg/mL.
- Accession
- Q9EP73-1
- Animal free
No
- Species
Mouse
- Reconstitution
Reconstitute with sterile deionized water to a concentration of 400 µg/ml.
- Concentration
- Storage buffer
pH: 7.4
Constituents: 95% PBS, 5% Trehalose
Sequence info
Amino acid sequence
F T I T A P K D L Y V V E Y G S N V T M E C R F P V E R E L D L L A L V V Y W E K E D E Q V I Q F V A G E E D L K P Q H S N F R G R A S L P K D Q L L K G N A A L Q I T D V K L Q D A G V Y C C I I S Y G G A D Y K R I T L K V N A P Y R K I N Q R I S V D P A T S E H E L I C Q A E G Y P E A E V I W T N S D H Q P V S G K R S V T T S R T E G M L L N V T S S L R V N A T A N D V F Y C T F W R S Q P G Q N H T A E L I I P E L P A T H P P Q N R T
- Accession
- Protein length
Fragment
- Predicted molecular weight
51.8 kDa
- Amino acids
19 to 238
- Nature
Recombinant
- Tags
Fc tag C-Terminus
Specifications
- Form
Lyophilized
General info
- Function
Plays a critical role in induction and maintenance of immune tolerance to self (PubMed:11238124). As a ligand for the inhibitory receptor PDCD1/PD-1, modulates the activation threshold of T-cells and limits T-cell effector response (PubMed:11238124). Through a yet unknown activating receptor, may costimulate T-cell subsets that predominantly produce interleukin-10 (IL10) (PubMed:11015443, PubMed:12719480).
- Sequence similarities
Belongs to the immunoglobulin superfamily. BTN/MOG family.
- Post-translational modifications
Ubiquitinated; STUB1 likely mediates polyubiquitination of PD-L1/CD274 triggering its degradation.
- Subcellular localisation
Early endosome membrane, Recycling endosome membrane
Storage
- Shipped at conditions
Blue Ice
- Appropriate long-term storage conditions
-20°C
- Aliquoting information
Upon delivery aliquot
- Storage information
Avoid freeze / thaw cycle
This product is an active protein and may elicit a biological response in vivo, handle with caution.
Notes
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
Supplementary info
This supplementary information is collated from multiple sources and compiled automatically.
- Activity summary
PD-L1 also known as Programmed Death-Ligand 1 or CD274 is a protein involved in immune modulation. Mechanically PD-L1 interacts with its receptors particularly PD-1 to regulate cellular immune responses. This transmembrane protein has a calculated molecular weight of approximately 33 kDa. PD-L1 is expressed on various cell types including tumor cells and immune cells such as dendritic cells macrophages and B cells. Its expression is often upregulated in response to inflammatory cytokines.
- Biological function summary
PD-L1 plays a central role in immune evasion mechanisms utilized by tumors. It is not part of a larger protein complex but directly interacts with PD-1 and CD80. When PD-L1 binds to PD-1 it sends inhibitory signals leading to decreased T cell activation and proliferation allowing cancer cells to avoid immune destruction. PD-L1 expression provides a mechanism for tumors to suppress immune surveillance facilitating tumor progression.
- Pathways
PD-L1 is integral to the immune checkpoint pathway which is an important regulator of immune response. The interaction between PD-L1 and PD-1 provides a mechanism for immune tolerance which is part of the broader adaptive immune system pathway. PD-L1 is related to other immune checkpoint proteins such as CTLA-4 in its function to limit autoreactivity and promote immune homeostasis.
- Associated diseases and disorders
PD-L1 is most associated with cancer particularly in tumors such as melanoma and non-small cell lung cancer. PD-L1 expression on tumor cells often correlates with poor prognosis. PD-L1 directly interacts with PD-1 in these cancers a target for immunotherapies such as checkpoint inhibitors which aim to block this interaction and restore immune activity against tumors. PD-L1 involvement extends to autoimmune disorders where altered expression can impact tolerance and lead to immune-related tissue damage.
Product promise
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
3 product images
ELISA - Recombinant mouse PD-L1 protein (Fc Chimera Active) (ab221310)
Immobilized Recombinant Mouse CD80 protein (Fc Chimera) (ab207101) at 5 μg/mL (100 μL/well) can bind ab221310 with a linear range of 0.16-2.5 μg/mL.
ELISA - Recombinant mouse PD-L1 protein (Fc Chimera Active) (ab221310)
Immobilized ab221310 at 5 μg/mL (100 μL/well) can bind Recombinant mouse PD1 protein (Active) (Biotin) (ab246151) with a linear range of 0.313-5 μg/mL.
SDS-PAGE - Recombinant mouse PD-L1 protein (Fc Chimera Active) (ab221310)
SDS-PAGE analysis of reduced ab221310 stained overnight with Coomassie Blue.
The protein migrates as 65-85 kDa on a SDS-PAGE gel under reducing conditions due to glycosylation.
Downloads
Product protocols
- Visit the general protocols
- Visit troubleshooting
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com